LGI1 and epilepsy: Zhong R et al. reported on 14 patients with anti-GABABR AE, of whom 10 (71.4%) developed SE and 6 (42.9%) developed epilepsy after the acute phase of encephalitis, a much higher proportion than in anti-NMDAR AE or anti-LGI1 AE (13).